Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
Prevalence and risk factors for cerebral microbleeds in elderly Chinese patients with arteriosclerotic cardiovascular diseases: A single-center study
The objective of the study was to explore the prevalence and risk factors of cerebral microbleeds (CMBs) in elderly ( ≥ 65 years old) Chinese people with ASCVD.
Source: Journal of Stroke and Cerebrovascular Diseases - July 22, 2023 Category: Neurology Authors: Yuhui Chen, Fang Liu, Juan Chen, Dongdong Wu, Jing He, Min Chen, Yinhong Liu Source Type: research
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Proprotein convertase subtilisin/kexin type 9 (PCSK9) interacts with the low-density lipoprotein (LDL) receptor and, by enhancing its degradation, has a pivotal role in the regulation of cholesterol homeostasis. Two fully humanized monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, are available for clinical use. PCSK9 inhibitors reduce LDL-C 30% more than ezetimibe and 60% more than placebo when added to statins. This reduction in LDL-C is accompanied by a decrease in the risk of major cardiovascular and cerebrovascular events.
Source: Journal of Stroke and Cerebrovascular Diseases - August 24, 2021 Category: Neurology Authors: Bayan Moustafa, Fernando D Testai Tags: Review Article Source Type: research
Statins for the Prevention of Post-Stroke Seizure and Epilepsy Development: A Systematic Review and Meta-Analysis
Cerebrovascular disease is the leading cause of seizures and incident epilepsy of known etiology in older adults. Statins have increasingly garnered attention as a potential preventive strategy due to their pleiotropic effects beyond lipid-lowering, which may include neuroprotective and anti-epileptogenic properties. We aim to assess the evidence on statin use for prevention of post-stroke early-onset seizures and post-stroke epilepsy.
Source: Journal of Stroke and Cerebrovascular Diseases - August 23, 2021 Category: Neurology Authors: Emily K. Acton, Ossama Khazaal, Allison W. Willis, Michael A. Gelfand, Sean Hennessy, Magdy H. Selim, Scott E. Kasner Source Type: research
Controversies: Stroke Prevention in Chronic Kidney Disease
Risk of both ischemic and hemorrhagic stroke is increased in the chronic kidney disease (CKD) population, particularly in end-stage kidney disease patients. Uremic factors that contribute to stroke risk include blood pressure variability, vascular calcification, build-up of vascular toxins, chronic inflammation, platelet dysfunction and increased brain microbleeds. This paper discusses the controversial evidence for stroke prevention strategies including blood pressure control, statins, antiplatelet agents, and anticoagulation in the CKD population.
Source: Journal of Stroke and Cerebrovascular Diseases - February 25, 2021 Category: Neurology Authors: Wei Ling Lau Source Type: research
Therapeutic Effects of Iron Chelation in Atorvastatin-Induced Intracranial Hemorrhage of Zebrafish Larvae
Intracranial hemorrhage (ICH) acutely and severely damages brain function.1,2 The prognosis of ICH is poor due to the drastic and rapid progression of its pathology, and the lack of effective treatments presents a significant unmet clinical need. Therefore, novel therapeutic agents for ICH have the potential to significantly improve clinical outcomes. The collagenase-induced rodent ICH model is the most commonly used experimental ICH model.3 However, detailed live imaging of hematoma development in rodent models is inherently limited, as rodents are opaque.
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Shinsuke Nakamura, Yuichi Saito, Takumi Gouda, Takahiko Imai, Masamitsu Shimazawa, Yuhei Nishimura, Hideaki Hara Source Type: research
Use of statins for the secondary prevention of stroke: are we respecting the scientific evidences?
Background: Stroke accounts for approximately as 5.0% of disability-adjusted years of life and 10.0% of all deaths worldwide. Secondary stroke prevention in surviving individuals, which includes the use of statins, reduces atherothrombotic stroke recurrence, complications and mortality. The present study aimed to characterize the Brazilian population with stroke history and estimate the prevalence of statin use as secondary prevention.Methods: This is a population-based cross-sectional study conducted in Brazilian urban areas.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2020 Category: Neurology Authors: Jo ão Paulo Vilela Rodrigues, Lucas Borges Pereira, Maria Olívia Barboza Zanetti, Andréia Turmina Fontanella, Nereida Kilza da Costa Lima, Sotero Serrate Mengue, Leonardo Régis Leira Pereira Source Type: research
Statin Pretreatment Might Be Associated with Decreased Myocardial Injury After Ischemic Stroke
In this study, we aimed at investigating the association between statin pretreatment and poststroke myocardial injury. Methods: Six hundred seventy-one patients diagnosed as acute ischemic stroke were enrolled. According to the histories of statin pretreatment before stroke, patients were categorized into nonstatin (n = 474) and statin groups (n = 197), with the latter further divided into low-dosage, standard-dosage, and high-dosage subgroups according the dosages of statins.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2020 Category: Neurology Authors: Ke-Wu Wang, Chao Feng, Yin-Fei Wu, Jing Huang, Wen-Bo Xiao, Shu-Dong Xia Source Type: research
Apolipoproteins B and A1 in Ischemic Stroke Subtypes
Introduction: Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and intracranial atherosclerotic disease. We sought to assess the relationship between serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio with ischemic stroke subtypes and large artery atherosclerosis location. Materials and Methods: We evaluated serum apolipoprotein B and apolipoprotein A1 levels in consecutive, statin-na ïve, adult ischemic stroke patients admitted to an academic medical center in southern India.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2020 Category: Neurology Authors: Rizwan Kalani, Soumya Krishnamoorthy, D. Deepa, Srinivas Gopala, Dorairaj Prabhakaran, David Tirschwell, P.N. Sylaja Source Type: research
Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population
Background and purpose: Previous studies have shown that common variants within CYP3A4 and CYP3A5 are associated with statin pharmacokinetics and the risk of cardiovascular disease. However, the association of variants in CYP3A4 and CYP3A5 with the prognosis of ischemic stroke remains undetermined. Therefore, we investigated this herein. Methods: Four hundred thirty-three consecutive patients with acute ischemic stroke were recruited. The outcome at the 1-year follow-up was assessed using the modified Rankin Scale (mRS).
Source: Journal of Stroke and Cerebrovascular Diseases - May 3, 2019 Category: Neurology Authors: Shuo Li, Chang-he Shi, Xin-jing Liu, Yu-sheng Li, Shao-hua Li, Bo Song, Yu-ming Xu Source Type: research
Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis
Background: The association of lipid lowering therapy and intracerebral hemorrhage risk is controversial. Methods: We performed a cumulative meta-analysis of lipid lowering trials that reported intracerebral hemorrhage. Statin, fibrate, ezetimibe, PCSK9, and CETP trials were included. We explored whether the association of lipid lowering therapy and risk of intracerebral hemorrhage may vary by baseline low-density lipoprotein (LDL) level, mean change in LDL or baseline cardiovascular risk of population.
Source: Journal of Stroke and Cerebrovascular Diseases - March 12, 2019 Category: Neurology Authors: Conor Judge, Sarah Ruttledge, Maria Costello, Robert Murphy, Elaine Loughlin, Alberto Alvarez-Iglesias, John Ferguson, Sarah Gorey, Aoife Nolan, Michelle Canavan, Martin O'Halloran, Martin J. O'Donnell Source Type: research
Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography
Background: The present study aimed to explore the efficacy of atorvastatin on patients with carotid plaque, applying superb microvascular imaging (SMI), and contrast-enhanced ultrasound (CEUS) for evaluating carotid intraplaque neovascularization. Methods: A total of 82 patients (82 carotid plaques) who were randomized into treatment group and control group underwent conventional ultrasound, CEUS, and SMI examinations. Patients in treatment group received a dose of 20 mg atorvastatin per day for 6 months while those in control group received placebo instead.
Source: Journal of Stroke and Cerebrovascular Diseases - December 15, 2018 Category: Neurology Authors: Yi-Cheng Zhu, Xiao-Zhen Jiang, Qing-Ke Bai, Shu-Hao Deng, Yuan Zhang, Zhi-Peng Zhang, Quan Jiang Source Type: research
Low Testosterone Level as a Predictor of Poststroke Emotional Disturbances: Anger Proneness and Emotional Incontinence
The role of sex hormones in poststroke mood and emotional disturbances is unclear. We aimed to evaluate the impact of sex hormones on poststroke emotional disturbance, especially anger proneness (AP) and emotional incontinence (EI). We also investigated whether statins, which are widely used for stroke prevention, affect sex hormone levels or the presence of poststroke AP/EI based on the hypothesis that intensive treatment with statins would inhibit the synthesis of cholesterol, the preferred substrate of testosterone.
Source: Journal of Stroke and Cerebrovascular Diseases - September 6, 2018 Category: Neurology Authors: Mun Hee Choi, Tae Sung Lim, Bok Seon Yoon, Keoung Sun Son, Ji Man Hong, Jin Soo Lee Source Type: research
Statin Use and the Risk of Dementia in Patients with Stroke: A Nationwide Population-Based Cohort Study
Background: Patients with stroke have an increased risk of dementia. Some studies have found that statin use might lower the risk of incident dementia; however, there is still a lack of data from patients with stroke. Therefore, the aim of our study was to investigate the impact of statin use on the risk of dementia in patients with stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Mei-Lien Pan, Chien-Chi Hsu, Yi-Min Chen, Hui-Kung Yu, Gwo-Chi Hu Source Type: research
Atorvastatin Pretreatment Attenuates Ischemic Brain Edema by Suppressing Aquaporin 4
Background: Cerebral edema, a serious complication of acute cerebral infarction, has a crucial impact on morbidity and mortality in the early stage of cerebral infarction. And aquaporin 4 (AQP4), a bidirectional water transporting protein, plays a pivotal role in edema formation. At experimental model, it has proven that atorvastatin could exert pleiotropic neuroprotection on acute cerebral infarction independent of its cholesterol-lowering action. It was a common protective manifestation that atorvastatin can reduce the infarct volume and cerebral edema.
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Zhi-Juan Cheng, Ting-Min Dai, Yao-Yao Shen, Jian-Le He, Juan Li, Jiang-Long Tu Source Type: research
Clinical Study of Intracranial and Extracranial Atherosclerotic Stenosis in Spontaneous Intracerebral Hemorrhage Patients
Nowadays, researchers had begun to focus on the use of antiplatelet and statins in patients with spontaneous intracerebral hemorrhage (sICH), but atherosclerosis treatment remains uncertain in these patients. We aimed to investigate the incidence and characteristics of intracranial and extracranial atherosclerotic stenosis in these patients and analyze its related risk factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 8, 2017 Category: Neurology Authors: Chun-Yang Zhang, Shi-Ren Huang, Si-Yang Wang, Lei Shen, Ben-Qiang Deng Source Type: research
